Alivus Life Sciences

Alivus Life Sciences delivered a strong Q4 FY26 with revenue of 689 croreCurrent reported value: 689 crore. No comparable prior figure is available in the source record. (+6.1Current reported value: 6.1. No comparable prior figure is available in the source record.% YoY) and EBITDA margin of 34.4%Current 34.4% vs previous available quarter 36.4%. (+230 bps YoY), driven by favorable product mix, cost discipline, and non-GPL growth (71%Current 71%. Reported change: +12pp YoY. of revenue). Full-year revenue reached 2,552 croreCurrent reported value: 2,552 crore. No comparable prior figure is available in the source record. (+6.9% YoY) with EBITDA margin of 33.6%Current reported value: 33.6%. No comparable prior figure is available in the source record. (+366 bps). Management guided EBITDA margins of 30-32% for FY27, citing backward integration benefits from Solapur (operational Q2 FY27) and sustained non-GPL momentum. Key risks include tariff uncertainties, raw material cost inflation from geopolitical tensions, and potential delays in CDMO deal closures.